This isn’t an easy topic to write about nor is it an easy topic to find information about since it’s quite complex. However, we will share with you as much information as possibly can about this subject so that you no longer have any questions left un-answered by the end of this article.
Stay Up-To-Date With The Latest From Drugbank!
Venous thromboembolism, pulmonary embolism, thromboembolism with atrial fibrillation, thromboembolism with cardiac valve replacement, and thromboembolic events post myocardial infarction. Also used for anticoagulant prophylaxis. Acenocoumarol An anticoagulant drug used in the prevention of thromboembolic diseases in infarction and transient ischemic attacks, as well as management of deep vein thrombosis and myocardial infarction.
Ethyl biscoumacetate Ethyl biscoumacetate is a courmarin that is used as an anticoagulant. Diphenadione Not Annotated
Tioclomarol Not Annotated
4-hydroxycoumarin Not Available
(R)-warfarin Warfarin consists of a racemic mixture of two active enantiomers—R- and S- forms—each of which is cleared by different pathways. S-warfarin is 2-5 times more potent than the R-isomer in.
Save Citation To File
been the mainstay of anticoagulation therapy for more than 50 years. Vkas are mainly used for the prevention of stroke in patients with atrial fibrillation (AF) and the treatment and secondary prevention of venous thromboembolism. Despite these new treatment options, the VKA warfarin currently remains the most frequently prescribed oral anticoagulant.
The availability of DOACs provides an alternative management option for patients with AF, especially when the treating physician is hesitant to prescribe a VKA owing to associated limitations, such as food and drug interactions, and concerns about bleeding complications. Treatment decisions on which DOAC is best suited for which patient to maximize safety and effectiveness should take into account not only clinically relevant patient characteristics but also patient preference.
Associated Data
Login To Your Account
Fang MC
et al.
Vitamin K antagonists have been successfully used for more than 50 years as oral anticoagulant drugs in patients at risk of venous or arterial thromboembolism. Because of a narrow therapeutic window and an unpredictable dose response, regular laboratory monitoring is mandatory. Portable monitoring devices have become available, which offer the opportunity for patients to undertake INR tests themselves (self-testing) and to make their own dose adjustments (self-management).
Self-monitoring is attractive not only because it offers flexibility and self-determination but also because it can improve the quality of anticoagulatio.